Lütticken R, Wannamaker L W, Kluitmann G, Neugebauer M, Pulverer G
Dtsch Med Wochenschr. 1976 Jun 18;101(25):958-63. doi: 10.1055/s-0028-1104196.
Sera from normal controls from patients with streptococcal diseases, and from other patients whose serum was sent for anti-streptolysin 0 determinations were tested for antistreptolysin 0 (ASO) and anti-DNase B (ADB) antibodies. The Streptozyme test was performed on the same sera. The upper limits of normal in the control population were established as 160 units for ASO and as 240 units for ADB, respectively. The usefulness of the ADB test in addition to the ASO test was confirmed: when both tests were performed elevated titers could be demonstrated in a higher percentage of various streptococcal diseases. With respect to streptococcal infections of the skin the anti-DNase B-test was superior to the ASO test. In this study of the Streptozyme test showed an elevated antibody titer in a lower proportion than the other two tests.
对来自链球菌疾病患者的正常对照者、血清送检进行抗链球菌溶血素O测定的其他患者的血清,检测其抗链球菌溶血素O(ASO)和抗脱氧核糖核酸酶B(ADB)抗体。对相同血清进行链激酶试验。对照人群中ASO的正常上限分别确定为160单位,ADB为240单位。证实了除ASO试验外,ADB试验的有用性:当两项试验都进行时,在更高比例的各种链球菌疾病中可显示出滴度升高。就皮肤链球菌感染而言,抗脱氧核糖核酸酶B试验优于ASO试验。在这项研究中,链激酶试验显示抗体滴度升高的比例低于其他两项试验。